Clinical Trial Update: A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in asthma evaluating the efficacy and dose-response of repeat dosing with GW870086X on FEV1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GW870086X

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED